Brain Cancer

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.

Mirdametinib led to sustained, significant, and clinically meaningful improvements in HRQOL in adults and children with NF1-PN.

Larotrectinib produced rapid and durable responses and a high DCR in pediatric patients with TRK fusion–positive primary central nervous system tumors.

Timothy Gershon, MD, PhD, discusses an analysis of patients with NF1-PN who achieved deep responses with mirdametinib in the phase 2b ReNeu study.

Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.

Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.

IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.

The NMPA has approved belzutifan for von Hippel-Lindau disease in RCC, CNS hemangioblastomas, or pNETs not requiring immediate surgery.

The FDA has granted orphan drug designation to the herpes simplex virus type 1 oncolytic virus MB-108 for the management of malignant glioma.

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.

The FDA has accepted and granted priority review to the new drug application for the glioma imaging agent TLX101-CDx.

LP-184 has received fast track designation from the FDA for the treatment of patients with glioblastoma.

LMP744 has been granted orphan drug designation by the FDA for the treatment of patients with glioma.

An update on PFS and OS data from the phase 1 MAGIC-G1 study of MTX110 in recurrent glioblastoma has been released.

The FDA has granted rare pediatric disease designation to LP-184 in malignant rhabdoid tumors, rhabdomyosarcoma, and hepatoblastoma.

The phase 2 trial of the gamma-delta T-cell therapy INB-400 plus temozolomide in patients with newly diagnosed GBM has suspended enrollment.

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

Seema Nagpal, MD, discusses the significance of the FDA approval of vorasidenib for adult and pediatric patients with IDH1/2-mutant glioma.

Seema Nagpal, MD, discusses the FDA approval of vorasidenib for patients with astrocytoma or oligodendroglioma harboring IDH1 or IDH2 mutations.

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

An NDA has been submitted to the FDA for TLX101-CDx for the characterization of progressive or recurrent glioma in adult and pediatric patients.

Opaganib has received orphan drug designation from the FDA for use in patients with neuroblastoma.

The FDA has awarded rare pediatric disease designation and orphan drug designation to INV724 for the treatment of neuroblastoma.

Rhenium obisbemeda proved feasible and safe for patients with leptomeningeal metastases in an interim analysis of the phase 1 ReSPECT-LM trial.